MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Netherlands Cancer Institute
Amsterda, HolandaPublicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (7)
2022
-
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160
2021
-
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
Annals of Oncology
-
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524
2018
-
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
Journal of Clinical Oncology, Vol. 36, Núm. 24, pp. 2465-2472
2005
-
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583